Management Team

BioNTech’s international Management team is highly experienced with backgrounds spanning academia, big pharma, entrepreneurial and innovative emerging biopharma and many geographies including USA, UK and Europe.

Management Board

Prof. Dr. Ugur Sahin

Prof. Dr. Ugur Sahin

Co-Founder and CEO

Prof. Sahin, Ph.D. is an entrepreneurial researcher and inventor who has made essential contributions to more than 60 independent patents in various life science and biotechnology fields, including pioneering innovations that provide the basis for the foundation of BioNTech AG.

Sean Marett

Sean Marett

COO

Sean Marett has 30 years of international experience in the management of operations, sales and marketing licensing, M&A and new product development.

Dr. Sierk Poetting

Dr. Sierk Poetting

CFO

Sierk Poetting, Ph.D. has worked for large pharma companies covering a broad range of responsibilities, such as integrating several acquired companies, supporting the execution of numerous M&A and licensing deals.

Vice Presidents

Prof. Dr. Katalin Karikó

Prof. Dr. Katalin Karikó

Vice President RNA Protein Replacement Therapy BioNTech RNA Pharmaceuticals GmbH

Prof. Katalin Karikó, Ph.D. leads the mRNA-based protein replacement program for BioNTech RNA Pharmaceuticals GmbH. She has more than 30 years of experience working with RNA.

Dr. Andreas Kuhn

Dr. Andreas Kuhn

Vice President RNA Biochemistry BioNTech RNA Pharmaceuticals GmbH

Andreas Kuhn, Ph.D. has worked in the field of RNA biochemistry and molecular biology for more than twenty years.

Dr. Heinrich Haas

Dr. Heinrich Haas

Vice President Drug Delivery BioNTech RNA Pharmaceuticals GmbH

Heinrich Haas, Ph.D. has more than 18 years of experience in academic research and industrial pharmaceutical development. After he received his Ph.D. in physical chemistry, Dr. Haas researched lipid membranes and organized biomolecular systems.

Dr. Michael Oed

Dr. Michael Oed

Vice President Product Development BioNTech Diagnostics GmbH

Michael Oed, Ph.D. has more than 25 years of professional experience in design, development, manufacturing, clinical validation and national/international regulatory approval of in vitro diagnostic devices (IVDs).

Dr. Sylke Maas

Dr. Sylke Maas

Vice President Sales and Marketing BioNTech AG

Sylke Maas, Ph.D. is responsible for Global Marketing and Sales at BioNTech AG. Before joining BioNTech AG, she was a partner at InterPharmaLink, a consulting pharmaceutical company focused on commercial strategy, enterprise development and partnering.

Dr. Oliver Hennig

Dr. Oliver Hennig

Vice President Operations BioNTech AG

Oliver Hennig, Ph.D. is an experienced project and product lifecycle manager who has been implementing these methodologies, using various business models, for products and solutions on a global scale.

Dr. Markus Werner

Dr. Markus Werner

Vice President Business Development BioNTech AG

Markus Werner, Ph.D. is a molecular bioengineer by training and has more than 16 years of experience in pharmaceutical collaborations and partnerships. During his tenures he has held various business development positions in biotech, generics and pharma industry.

Dr. Felicitas Müller

Dr. Felicitas Müller

Vice President Scientific Alliances BioNTech AG

Felicitas Müller, Ph. D. is responsible for content related coordination of the scientific cooperations at BioNTech. She holds a doctorate in clinical biochemistry and pathobiochemistry and spent several years as an academic researcher at the Karolinska Institute in Sweden.

Scientific Advisory Board

Prof. Dr. Rolf Zinkernagel

Prof. Dr. Rolf Zinkernagel is Professor Emeritus at the University of Zurich, University Hospital, Zurich and former head of the Institute of Experimental Immunology, Zurich.

Prof. Dr. Hans Hengartner

Prof. Dr. Hans Hengartner is Professor Emeritus at the Federal Institute of Technology ETH Zurich and University of Zurich.

Dr. Özlem Türeci

Özlem Türeci, Ph.D. is an MD with over 20 years’ experience in cancer research. Her focus is the identification of immunotherapeutic drug targets and development of antibody as well as vaccine based therapies for non-hematological cancers.

Executive Advisors

Sebastian Kreiter, M.D.

Sebastian Kreiter, M.D.

Sebastian Kreiter, M.D. developed the fundamentals of the Ribological® RNA vaccine platform under the guidance of Ugur Sahin. They have been working together since 2001.

Dr. Mustafa Diken

Dr. Mustafa Diken

Mustafa Diken, Ph.D. received his Ph.D. in tumor immunology from Johannes Gutenberg University, Mainz and is currently the Deputy Director of the Immunotherapy Development Center at TRON GmbH.